The effects of acute administration of human recombinant insulin-like growth factor-I (rhIGF-I) on amino acid (AA) flux between hindlimbs, liver and gut were investigated in anaesthetized post-operative dogs. rhIGF-I produced about a 10-fold increase in plasma IGF-I concentrations above baseline values (P < 0.001), increased the plasma levels of glucagon and adrenaline (P < 0.05), and evoked a fall in plasma glucose (-55 + 8 %; P < 0.001) and plasma total AA levels (-23 + 8 %; P < 0.05).
INTRODUCTION
Insulin-like growth factor-I (IGF-I) is a polypeptide with Mr 7600 that is structurally related to insulin [1] . IGF-I produces a variety of metabolic effects. At supraphysiological doses, IGF-I lowers blood glucose in non-diabetic animals and humans, with a hypoglycaemic potency of 1.5-7% compared with that of insulin on a molar basis [2] . IGF-I stimulates growth in several pathophysiological conditions associated with low IGF-I levels, e.g. hypophysectomized rats [3] , diabetic rats [4] and Snell dwarf mice [5] .
In mediating these effects, IGF-I not only stimulates cell growth but also increases protein accretion. It was shown that IGF-I accelerates amino acid (AA) uptake from hepatocytes [6] , increases net protein synthesis in cartilage [7] , enhances tyrosine incorporation in isolated muscles of lean mice [8] and lowers circulating AAs by decreasing protein breakdown in normal rats [9] . Prolonged infusions of IGF-I increase body weight in thermally injured rats [10] , decrease the rate of loss of protein in lambs during infusion of recombinant tumour necrosis factor [1 1] and reverse diet-induced catabolism in humans [12] , but are ineffective in improving nitrogen balance in normal human subjects [13] .
The mechanisms involved in these changes of AA metabolism are not yet clear. Therefore the purpose of this study was to investigate the influence of recombinant human (rh) IGF-I on the inter-organ transfer of AAs in dogs. We performed our study in a catabolic situation where amino nitrogen is delivered from skeletal muscle to the liver.
METHODS

Animal preparation
Male Beagle dogs aged about 2 years and weighing [10] [11] [12] [13] [14] [15] kg were used. The dogs were fasted overnight (12 h ). On the morning the gut and an AA uptake by the liver. The administration of rhIGF-I increased hepatic AA uptake in the NaCl group from 3.51 +0.8 to 7.5 +0.4,umol/min per kg (P < 0.01) and in the AA-infused group from 16.8 +0.6 to 22.4+ 1.5 ,tmol/min per kg (P < 0.05), but did not influence the AA balance across hindlimbs and gut. Glucose infusions normalized the plasma concentrations of counter-regulatory hormones without influencing the interorgan AA balances. We conclude that hypoaminoacidaemia caused by rhIGF-I infusions is the result of a stimulated AA uptake by the liver, but is unrelated to alterations of AA exchange across the hindlimbs.
of the study all dogs were subjected to general anaesthesia using N20/02 (1: 1) plus 0.5 % halothane. Laparotomy was performed through a midline abdominal incision for placement of silicone rubber catheters (1 mm inner diameter, 2.2 mm outer diameter; Dow Corning, Midland, MI, U.S.A.). The catheters were implanted into the femoral artery, portal vein, hepatic vein and femoral vein as described previously [14, 15] . Another catheter was placed in the internal jugular vein and was used for infusion of the substrates: saline (0.9 % NaCl), AAs, glucose and rhIGF-I. Flow probes of appropriate inner and outer diameters (Heilige G.m.b.H., Freiburg, Germany) were placed around the vena cava and the portal vein. The operation and the implantation of the catheters took about 1 h. The experiment was started 30 min after completion of these procedures. Adrenaline and noradrenaline were analysed by h.p.l.c. with electrochemical detection [16] .
Experimental design
Blood samples for determination of plasma AAs (2 ml) were drawn in heparinized syringes. For determination of AAs, 1 ml of plasma was deproteinized with 0.1 ml of 3 % sulphosalicylic acid containing fl-thienylalanine (1 nM) as the internal standard.
After centrifugation, 1 part of the sample was diluted with 99 parts of water containing 2 mmol of NaN3. The AAs were analysed by automatic pre-column derivative formation with ophthalaldehyde and h.p.l.c. separation [17] , with some modifications as described previously [14] .
Blood flow in the artery and portal vein was measured electromagnetically and was corrected for the corresponding packed cell volume to obtain plasma flow values. The hindlimb was assumed to contain 25% of the total skeletal muscle; therefore, plasma (blood) flow in the hindlimb was multiplied by 4 to calculate plasma (blood) flow of the total skeletal muscle [18] . The hepatic and muscle plasma flows determined in the present experiment were similar to those that we and others had reported previously [14, 15, 18] .
Calculation and statistics
Net release or removal of AAs was calculated by multiplying the arteriovenous plasma concentration differences by the rate of plasma flow. In the liver there is a dual supply of substrates, i.e. via the portal vein and the hepatic artery. It was assumed that 72 % of the hepatic blood flow was via the portal vein and 28 % via the hepatic artery [19, 20] . These plasma flow values were multiplied by the respective concentrations in the portal vein and artery to calculate the total amount of substrate inflow into the liver. Balances across the hindlimbs were assumed to be representative of balances across skeletal muscle. We Analysis of variance with repeated measures was used to determine whether there was a difference between the values obtained for the experimental and control groups respectively. Analysis of statistical differences were performed by using Wilcoxon's matched-pairs signed rank test, and (exact permutational) P values were derived in view of the small sample size. All data are expressed as means+ S.E.M.
RESULTS
Anaesthesia and operation procedures (abdominal incision, catheter insertion) increased the pre-operative plasma levels of glucose from 5.8+0.16 to 7.0+0.27mM (P < 0.01), of urea from 4.3 + 0.2 to 8.3 + 0.4 mM (P < 0.00 1) and of glucagon from 120 + 12 to 231 + 21 pg/ml (P < 0.01). The plasma levels of total AA (before, 2850 + 170, after, 2703 + 97 ,uM) and insulin (before, 10.6 + 0.9, after, 1 1.4 + 0.76 ,-units/ml) remained unchanged by the operation procedure. The post-operative values were measured 30 min after the end of the operation, immediately before the onset of the experimental procedures.
During the basal period, the average plasma flow rates in the hindlimbs, liver and gut of all dogs were 6.2 +0.2, 18.6+ 1.2 and 13.8 + 1.0 ml/min per kg. rhIGF-I infusions did not alter the blood flow in any of the tissue beds examined.
Effect of rhlGF-I on insulin, glucagon, adrenaline, noradrenaline and cortisol levels A 90 min infusion of rhIGF-I produced an 8-10-fold increase in plasma IGF-I concentrations above baseline, from 81+15 to -. Effect of rhlGF-I on AA metabolism
Arterial AA concentrations remained constant during NaCl infusions, but increased considerably during AA infusions (+ 71 % after 90 min). In both experimental conditions the addition of rhIGF-I significantly lowered the plasma [-24% (P < 0.05) in the NaCl group and -29 % (P < 0.01) in the AA group]. Glucose loading did not alter plasma AA levels ( Figure  1 ). Table 1 shows the arterial concentrations of individual AAs after 90 min of rhIGF-I infusion. The AA-lowering effect of rhIGF-I was found for virtually all AAs measured. During the saline infusion there was AA release from skeletal muscle and AA uptake by the liver and gut. Infusion of AAs decreased AA release from skeletal muscle (P < 0.05) and increased AA uptake by the liver (P < 0.001) and gut (0.53 + 0.31 versus 4.03 + 1.23; P < 0.05) ( Table 2) . rhIGF-I caused a moderate increase of peripheral release of AAs (not significant) and an increase of hepatic AA uptake (P < 0.01 in the NaCl group and P < 0.05 in the AA group). Gut AA balances became neutral under rhIGF-I and co-infusion of NaCl or glucose, and remained positive (uptake) under AA infusions. The glucose load had no additional influence on the AA balances.
Of the individual AAs, only alanine, glutamate and the branched-chain AAs valine, leucine and isoleucine were significantly affected ( Table 2 ). The infusion of rhIGF-I increased alanine [+ 76 % (P < 0.05) with NaCl and + 140 % (P < 0.05) with AA] release from skeletal muscle, and stimulated alanine uptake from the liver [NaCl infusion + 800% (P < 0.01); AA infusion + 60 % (P < 0.05)], but did not influence the alanine or glutamine balances across the gut (results not shown). Of the other AAs, IGF-I infusions evoked release of valine and leucine from the hindlimbs during NaCl infusion, and stimulated peripheral uptake of valine during AA infusion. In the liver, IGF-I evoked a higher extraction of glutamate (+ 82 %) and decreased the release of leucine and isoleucine during NaCl infusion.
The administration of rhIGF-I together with glucose to obtain normoglycaemic conditions had no additional effect on the interorgan balances of the measured AAs.
DISCUSSION
The infusion of rhGF-I in the first period resulted in significant hypoglycaemia, and this was associated with a rise in the plasma levels of the counter-regulatory hormones glucagon and adrenaline. During this period an associated fall in the plasma levels of all measured AAs occurred. Since we have not used radioisotopes during this study, we were unable to determine whether these changes are secondary to decreased protein breakdown, or are due to improved protein synthesis. The influence of rhIGF-I on protein turnover was measured in conscious fasted rats. In this study rhIGF-I evoked a decrease in leucine flux and a decline in the incorporation of [1-14C] leucine into muscle and liver protein, indicating an inhibition of tissue protein synthesis [9] . Similarly, rhIGF-I administration in lambs made catabolic by infusion of recombinant tumour necrosis factor resulted in a 15 % decrease in rate of net protein loss [11] .
At 90 min after start of rhIGF-I infusion, the plasma levels decreased by about 25 %. A similar effect of rhIGF-I on total plasma AA levels was found in conscious fasted rats [9] . In that study it was proved that this effect of rhIGF-I was independent of insulin, which is also known to be potent in decreasing plasma AA. This has been confirmed in our study, since mean plasma insulin values were not affected by the rhIGF-I infusion in the saline group or were even lowered in the dogs receiving AA.
Our study allowed us for the first time to differentiate which of the organs was most affected by rhIGF-I administration. From our data we cannot deduce the intra-hepatic utilization of the AAs taken up at a higher rate. Because of the lowered plasma glucose levels, it is unlikely that rhIGF-I increased the rate of gluconeogenesis. Therefore the increased hepatic uptake of AAs must have been due either to enhanced protein synthesis by the liver for resident proteins or secretory proteins, or to increased use of AAs for oxidation.
Unexpected was the finding that the net release of AAs across the hindlimbs was not decreased by rhIGF-I during both NaCl and AA infusions. In our experimental model, nitrogen is delivered from the hindlimbs to the gut and liver. This is a characteristic metabolic situation in the protein-catabolic state, where muscular proteins are degraded to AAs. Therefore, in this situation AA efflux is stimulated as compared with the conscious non-fasting state [14, 18, 21] . The reason for the lack of efficiency of rhIGF-I in reducing AA liberation from the skeletal muscle may be related to the hypoglycaemia with increased plasma levels of glucagon and adrenaline. Previous investigations have shown that hypoglycaemia is associated with the stimulation of protein breakdown [22] . Since the levels of both hormones returned to pre-infusion values during the euglycaemic state, and the effects of rhIGF-I on muscular AA release and on hepatic AA uptake were independent of whether the dogs were in hypoglycaemia or euglycaemia, a significant contribution of glucagon or adrenaline to the metabolic changes appears unlikely.
Data from muscle preparations indicate that AAs, and particularly the branched-chain AAs valine, isoleucine and leucine, are important in preventing protein breakdown [23] . On the other hand, studies by Abumrad et al. [24] have indicated that the uptake of AAs is dependent on the increase in AAs in the artery. Recently it was shown that a low dose of rhIGF-I failed to effect protein anabolism in normal volunteers [25] ; in that study, no alterations in plasma glucose concentration were observed. Rates of proteolysis, protein synthesis and leucine oxidation were unaffected by rhIGF-I administration. This failure of rhIGF-I to induce protein anabolism may be due to the lack of induction of pivotal growth-hormone-dependent serum cofactor(s) necessary for this effect, such as IGF-I binding protein-3.
In conclusion, we were able to demonstrate for the first time that the hypoaminoacidaemia occurring during rhIGF-I infusion results from a stimulated amino acid uptake by the liver. Even in the absence of AA infusions, rhIGF-I increased AA uptake across the liver. However, the maximal effect of rhIGF-I on AA uptake by the liver was achieved in the presence of abundant AA. In contrast, there was hardly any effect of rhIGF-I on the AA metabolism across the skeletal muscle or gut, in either the presence or the absence of AA infusion. This finding provides evidence that rhIGF-I was ineffective in reversing stimulated AA efflux from skeletal muscle in a catabolic state. However, a mediator which stimulates hepatic AA uptake in catabolic situations could be a valuable clinical tool for the treatment of catabolic patients, because impaired liver metabolism is a bad prognostic sign for these types of patients [26] .
